COMPASS Pathways Reports Positive Phase 3 Results in TRD

COMPASS Pathways ( (CMPS) ) has shared an update.

On February 17, 2026, COMPASS Pathways reported that its second Phase 3 trial, COMP006, met its primary endpoint, with two 25 mg doses of COMP360 psilocybin given three weeks apart showing a highly statistically significant and clinically meaningful reduction in Montgomery-Åsberg Depression Rating Scale scores versus a 1 mg dose at Week 6. Together with prior Phase 3 data from COMP005, the program shows rapid onset from the day after dosing, durable responses in a substantial subset of treatment-resistant depression patients out to at least 26 weeks after one or two treatments, and a generally well-tolerated safety profile, and the company has asked the U.S. Food and Drug Administration for a meeting to discuss a rolling review of a potential submission, underscoring its bid to advance a novel therapeutic option in a market with high unmet need.

Across COMP005 and COMP006, roughly one quarter to nearly 40% of patients on 25 mg COMP360 achieved clinically meaningful symptom reductions at Week 6, with many maintaining benefits over six months and some non-remitters converting to remission after a second dose, while most treatment-emergent adverse events such as headache, nausea, anxiety and visual hallucinations were mild to moderate and resolved within a day. Serious adverse events, including suicidal ideation, occurred at low rates and were more frequent in lower-dose or control arms in at least one case, and these Phase 3 results, involving more than 800 dosed participants across both trials, position COMP360 as a potential first-in-class, rapid-acting and durable pharmacological treatment for treatment-resistant depression, pending regulatory review.

The most recent analyst rating on (CMPS) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on COMPASS Pathways stock, see the CMPS Stock Forecast page.

Spark’s Take on CMPS Stock

According to Spark, TipRanks’ AI Analyst, CMPS is a Neutral.

The score is held back primarily by weak financial performance (no revenue, escalating losses/cash burn, and reduced equity with higher leverage). Offsetting this, technicals are trending positively and the latest earnings call highlighted significant Phase III/regulatory progress and a stated cash runway into 2027, while valuation remains constrained by ongoing losses and no dividend.

To see Spark’s full report on CMPS stock, click here.

More about COMPASS Pathways

COMPASS Pathways is a mental health care company focused on developing COMP360, a synthetic, proprietary formulation of psilocybin, as a treatment for difficult-to-treat psychiatric conditions, particularly treatment-resistant depression. Its pivotal clinical program in treatment-resistant depression comprises two large Phase 3 trials, COMP005 and COMP006, conducted across North America, Europe and the United States, building on earlier Phase 2b data in this indication.

Average Trading Volume: 1,361,794

Technical Sentiment Signal: Hold

Current Market Cap: $557.8M

For a thorough assessment of CMPS stock, go to TipRanks’ Stock Analysis page.